BioSpace News Archive

Siamab Therapeutics, Inc. today announced the publication of positive preclinical data for its ST1 antibody drug conjugate (ADC) in multiple models of ovarian cancer.

Higginbotham and Sellers-Patterson Insurance announced today the merger of their operations in Tyler, Texas.

According to the data published by Hexa Research, the U.S. medical cannabis market size was valued at USD 5.44 Billion in 2016 and is anticipated to reach USD 19.48 Billion by 2024.

Letco Medical, L.L.C. announces the launch of their Pharmacy Financial Services program, another in a series of new Letco Med offerings designed to partner with compounding pharmacies to grow their business and enhance profitability.

Alnylam Pharmaceuticals, Inc. announced today that it will report financial results for the second quarter ending June 30, 2018 on Thursday, August 2, 2018, before the U.S. financial markets open.

Four plaintiffs to receive $15,000 each, payable from legal fees; board certification to be uncoupled from membership

Vertex Pharmaceuticals announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion for SYMKEVI® in a combination regimen with ivacaftor for the treatment of people with cystic fibrosis aged 12 and older who either have two copies of the F508del mutation in the...

CIVCO Radiotherapy are excited to announce 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Adaptiiv’s 3D bolus software in the U.S.

MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, is scheduled to present at the 36th Annual J.P. Morgan Healthcare Conference

bluebird bio, Inc. (Nasdaq: BLUE) today announced the closing of its previously announced underwritten public offering of 3,892,308 shares of its common stock, including 507,692 shares of common stock sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a public offering price of $162.50 per share.